Gene and miRNA expression in radioiodine refractory and avid papillary thyroid carcinomas (miRNA expresseion dataset). Gene and miRNA expression in radioiodine refractory and avid papillary thyroid carcinomas (miRNA expresseion dataset)

We performed gene and miRNA expression profiling in a series of 39 papillary thyroid carcinomas (PTCs) and 13 matched non-neoplastic thyroids derived from PTC patients with metastatic disease and submitted to radioiodine (RAI) treatment. Overall design: Gene and miRNA expression profiles were established by microarray analysis in a retrospective series of 52 snap-frozen thyroid samples including 35 tissues collected before RAI treatment (17 primary PTC tumors, 5 synchronous lymph node metastases (LNMs), and 13 matched non-neoplastic thyroids included as control) and 17 RAI-refractory LNMs collected as successive surgery following RAI treatment. Patients were stratified based on RAI uptake at the metastatic site and on RAI response in either avid or refractory, displaying disease remission or persistance, respectively, after RAI treatment. Gene profiles were established by Thermo Fisher Human Clariom S Assay, and the corresponding miRNA profiles were established by Agilent SurePrint Human miRNA microarrays. Tumor samples were also characterized for the most common driving mutations and gene fusions typical of PTC by a PTC-Mass Array platform (PTC-MA).

本研究针对39例乳头状甲状腺癌（papillary thyroid carcinomas, PTC）组织，以及13例来源于伴转移且接受放射性碘（radioiodine, RAI）治疗的PTC患者的配对非肿瘤甲状腺组织，开展了基因与微小RNA（miRNA）表达谱分析。

总体设计：本研究通过微阵列分析，对52例速冻保存的甲状腺样本进行回顾性队列研究，以建立基因与miRNA表达谱。该队列包含35例RAI治疗前采集的组织：17例原发性PTC肿瘤、5例同期淋巴结转移灶（lymph node metastases, LNMs），以及13例作为对照的配对非肿瘤甲状腺组织；此外还包含17例RAI难治性淋巴结转移灶，此类样本采集自RAI治疗后接受后续手术的患者。

研究依据转移灶的RAI摄取水平以及RAI治疗应答类型对患者进行分层：RAI摄取阳性（RAI亲和型）患者在接受RAI治疗后可实现疾病缓解，而RAI难治型患者则在治疗后仍存在疾病持续状态。

基因表达谱通过赛默飞世尔科技（Thermo Fisher）Human Clariom S检测试剂盒完成构建与检测，对应的miRNA表达谱则采用安捷伦（Agilent）SurePrint人类miRNA微阵列完成检测。

同时，本研究采用PTC-Mass Array检测平台（PTC-MA），对肿瘤样本中乳头状甲状腺癌典型的常见驱动突变及基因融合事件进行了特征鉴定。